Sensus Healthcare, Inc. is a medical device company that provides non invasive treatment options for non melanoma skin cancer and for preventing keloid scars after surgery. The company’s core technology is superficial radiation therapy known as SRT which delivers low energy X ray beams to the skin surface. Sensus has developed a family of SRT based devices including the SRT 100 the SRT 100 plus and the SRT 100 Vision. As of the end of 2025 the company had installed 955…
Sensus Healthcare, Inc. is a medical device company that provides non invasive treatment options for non melanoma skin cancer and for preventing keloid scars after surgery. The company’s core technology is superficial radiation therapy known as SRT which delivers low energy X ray beams to the skin surface. Sensus has developed a family of SRT based devices including the SRT 100 the SRT 100 plus and the SRT 100 Vision. As of the end of 2025 the company had installed 955 units in 21 countries with the majority located in the United States. In addition to hardware the firm offers service programs such as the Sentinel maintenance plan and the Fair Deal Agreement revenue sharing model. The business was founded in 2010 and incorporated in Delaware before completing its initial public offering in 2016. Sensus continues to invest in research and development to expand its product portfolio and to improve patient access to non invasive skin cancer care.
Sensus Healthcare, Inc. generates revenue primarily from the sale of its SRT based radiation therapy systems. The company also earns income from service agreements that cover maintenance training and technical support. Under the Fair Deal Agreement model Sensus receives a percentage of the reimbursement collected by customers for SRT procedures. Additional revenue streams include financing programs that help customers acquire equipment and the sale of consumables such as disposable shielding and applicator tips. The firm serves private dermatology practices radiation oncology departments and other medical providers that seek non invasive skin treatment options. Service contracts provide recurring revenue streams that help stabilize cash flow. The company also generates income from the sale of consumable items such as disposable lead shielding and applicator tips that are used during each treatment session.
The company operates through the following segments.
• Single Operating Segment: this segment encompasses the design manufacture marketing and servicing of superficial radiation therapy devices and related healthcare services. Activities include the production of the SRT 100 the SRT 100 plus and the SRT 100 Vision systems the delivery of the Sentinel service program the administration of the Fair Deal Agreement revenue sharing model and the provision of financing solutions through Sensus Healthcare Financial Services.
Sensus Healthcare, Inc. occupies a niche position in the medical device market as a provider of superficial radiation therapy for skin conditions. The company competes with larger radiation equipment manufacturers that offer linear accelerator based systems and with manufacturers of alternative skin cancer treatments such as topical therapies and surgical devices. Sensus differentiates itself through its non invasive approach its low operating costs and its strong clinical evidence base that shows effective treatment outcomes for difficult to treat lesions. The firm also benefits from a growing reimbursement environment and from patents that protect its core technology. The company’s devices are designed for ease of use with automatic setup and user friendly interfaces which reduce the need for extensive training. Sensus also benefits from a strong intellectual property portfolio that includes multiple patents covering its SRT technology and related workflow management systems.
Sensus Healthcare, Inc. serves private dermatology clinics radiation oncology practices and other medical providers that treat skin lesions. The company’s customers include independent physician offices group practices and hospital based departments across the United States and in select international markets. The firm also works with distributors and resellers that help place its systems in regions outside of North America. Outside of the United States the company has placed systems in countries across Europe Asia and Latin America through a network of third party distributors. These international customers value the portability and low maintenance requirements of the SRT systems.
Sector:HealthcareSector rationaleSensus Healthcare designs and manufactures medical devices, specifically superficial radiation therapy (SRT) systems like the SRT 100, used to treat skin cancer. Its revenue is derived from the sale of these medical devices, related consumables (disposable shielding), and service agreements provided to dermatology and oncology practices.Industries:Medical DevicesHealthcarePrimarySensus Healthcare designs and manufactures therapeutic medical devices, specifically the SRT 100, SRT 100 plus, and SRT 100 Vision systems used for non-invasive treatment of skin cancer. These are radiation therapy systems sold to dermatology practices and radiation oncology departments.Medical SuppliesHealthcareSecondaryThe company generates revenue from the sale of consumables used during treatment sessions, specifically disposable lead shielding and applicator tips.Classified using BQ-MICSCIK: 0001494891
Investment Thesis
▲ Bull case
Sensus Healthcare (SRTS) is transitioning from a highly concentrated customer model to a diversified, recurring-revenue-driven business, with underlying growth excluding the largest customer showing year-over-year revenue increase from $2.7 million to $3.4 million, indicating organic expansion in a broader customer base. This diversification is being accelerated by the launch of Sensus Healthcare Financial Services, which provides flexible financing options and has already improved conversion rates on late-stage opportunities, while the shift toward outright purchases—now approximately 70% of systems shipped—suggests stronger customer confidence in the long-term value proposition under the new reimbursement environment. The company’s installed base of approximately 965 SRT systems globally represents a significant untapped opportunity for recurring revenue generation through SensusLink, which enables billing for radiation physics codes and creates a scalable, high-margin software revenue stream tied directly to treatment activity, a capability that did not exist prior to Q1 2026. Management’s strategic focus on market education and training on the new CPT codes—particularly the ~300% increase in the per-fraction delivery code—is already yielding measurable results, with treatment volumes increasing 8% year over year and growing engagement from dermatology practices, hospital systems, and private equity-backed platforms, all of which are contributing to a deeper, more qualified pipeline that leadership expects to convert into revenue in Q2 and beyond. The resolution of the SkinCure Oncology dispute removes a potential overhang on customer relationships and allows SRTS to redirect legal and operational resources toward commercial execution, reinforcing its commitment to expanding adoption without distraction. With $18.3 million in cash, no debt, and inventory increased to $16.5 million to meet anticipated demand, SRTS is financially positioned to support system placements under both direct sales and Fair Deal Agreement models while weathering the transition period, and the CEO’s confidence in achieving quarterly sequential profitability throughout 2026 reflects a disciplined expense management approach that has already reduced G&A, sales and marketing, and R&D costs versus the prior year.
Sensus Healthcare (SRTS) is transitioning from a highly concentrated customer model to a diversified, recurring-revenue-driven business, with underlying growth excluding the largest customer showing year-over-year revenue increase from $2.7 million to $3.4 million, indicating organic expansion in a broader customer base. This diversification is being accelerated by the launch of Sensus Healthcare Financial Services, which provides flexible financing options and has already improved conversion rates on late-stage opportunities, while the shift toward outright purchases—now approximately 70% of systems shipped—suggests stronger customer confidence in the long-term value proposition under the new reimbursement environment. The company’s installed base of approximately 965 SRT systems globally represents a significant untapped opportunity for recurring revenue generation through SensusLink, which enables billing for radiation physics codes and creates a scalable, high-margin software revenue stream tied directly to treatment activity, a capability that did not exist prior to Q1 2026. Management’s strategic focus on market education and training on the new CPT codes—particularly the ~300% increase in the per-fraction delivery code—is already yielding measurable results, with treatment volumes increasing 8% year over year and growing engagement from dermatology practices, hospital systems, and private equity-backed platforms, all of which are contributing to a deeper, more qualified pipeline that leadership expects to convert into revenue in Q2 and beyond. The resolution of the SkinCure Oncology dispute removes a potential overhang on customer relationships and allows SRTS to redirect legal and operational resources toward commercial execution, reinforcing its commitment to expanding adoption without distraction. With $18.3 million in cash, no debt, and inventory increased to $16.5 million to meet anticipated demand, SRTS is financially positioned to support system placements under both direct sales and Fair Deal Agreement models while weathering the transition period, and the CEO’s confidence in achieving quarterly sequential profitability throughout 2026 reflects a disciplined expense management approach that has already reduced G&A, sales and marketing, and R&D costs versus the prior year.
Sensus Healthcare (SRTS) faces persistent margin pressure and revenue recognition delays that are obscuring the true pace of its business model transition, with gross margin collapsing to 29.2% from 52.2% year over year due to a higher mix of lower-priced international shipments and upfront costs associated with Fair Deal Agreement (FDA) placements, which defer revenue recognition and contribute to near-term earnings volatility despite management’s optimism about long-term utilization benefits. The company’s reliance on the FDA program—evidenced by four of 14 systems shipped in Q1 being placed under this model—creates a structural headwind where revenue is recognized ratably over time rather than upfront, meaning that even as system placements grow, the associated revenue and gross profit will lag significantly behind unit shipments, potentially prolonging the path to profitability beyond management’s stated goal of quarterly sequential improvement in 2026. Although treatment volumes increased 8% year over year, this metric alone does not guarantee corresponding revenue growth, as a significant portion of the installed base remains under FDA or rental arrangements where monetization is utilization-dependent and subject to customer adoption cycles, and the company has not disclosed what percentage of its 965 installed systems are actively generating recurring revenue versus sitting idle or underutilized, raising concerns about the scalability and predictability of its software-driven revenue stream via SensusLink. The deepening adjusted EBITDA loss to negative $4.2 million from negative $2.5 million reflects worsening operational leverage during the transition, and while management cites reduced professional and lobbying expenses as drivers of lower operating costs, these savings may be temporary or offset by future investments needed to scale sales, support, and software infrastructure, particularly as the company expands into international markets like China where servicing costs are lower but regulatory and geopolitical risks remain unquantified. Finally, the absence of sales to the historically largest customer—while framed as a positive diversification step—creates a material revenue gap that has not yet been fully replaced by new customer acquisition, and until SRTS demonstrates consistent, sequential quarter-over-quarter revenue growth excluding one-time or deferred revenue components, the market remains justified in viewing the current results as a sign of weakening demand rather than a successful pivot to a recurring-revenue model.
Sensus Healthcare (SRTS) faces persistent margin pressure and revenue recognition delays that are obscuring the true pace of its business model transition, with gross margin collapsing to 29.2% from 52.2% year over year due to a higher mix of lower-priced international shipments and upfront costs associated with Fair Deal Agreement (FDA) placements, which defer revenue recognition and contribute to near-term earnings volatility despite management’s optimism about long-term utilization benefits. The company’s reliance on the FDA program—evidenced by four of 14 systems shipped in Q1 being placed under this model—creates a structural headwind where revenue is recognized ratably over time rather than upfront, meaning that even as system placements grow, the associated revenue and gross profit will lag significantly behind unit shipments, potentially prolonging the path to profitability beyond management’s stated goal of quarterly sequential improvement in 2026. Although treatment volumes increased 8% year over year, this metric alone does not guarantee corresponding revenue growth, as a significant portion of the installed base remains under FDA or rental arrangements where monetization is utilization-dependent and subject to customer adoption cycles, and the company has not disclosed what percentage of its 965 installed systems are actively generating recurring revenue versus sitting idle or underutilized, raising concerns about the scalability and predictability of its software-driven revenue stream via SensusLink. The deepening adjusted EBITDA loss to negative $4.2 million from negative $2.5 million reflects worsening operational leverage during the transition, and while management cites reduced professional and lobbying expenses as drivers of lower operating costs, these savings may be temporary or offset by future investments needed to scale sales, support, and software infrastructure, particularly as the company expands into international markets like China where servicing costs are lower but regulatory and geopolitical risks remain unquantified. Finally, the absence of sales to the historically largest customer—while framed as a positive diversification step—creates a material revenue gap that has not yet been fully replaced by new customer acquisition, and until SRTS demonstrates consistent, sequential quarter-over-quarter revenue growth excluding one-time or deferred revenue components, the market remains justified in viewing the current results as a sign of weakening demand rather than a successful pivot to a recurring-revenue model.